SOURCE: Streetwise Reports

Streetwise Reports

February 04, 2015 09:15 ET

Miraculins Inc. CEO Interviewed by BTV and The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Feb 4, 2015) - While other diseases catch headlines and media attention, diabetes has crept quietly into a full-blown, worldwide pandemic. With the Scout DS®, Winnipeg-based Miraculins Inc. (TSX VENTURE: MOM) is on the leading edge of medical innovation with the world's first noninvasive retail screening test for diabetes. In this interview with BTV and The Life Sciences Report, Miraculins President and CEO Christopher Moreau explains how the company is poised to expand into multiple markets to meet a desperate need for diabetes screening in North America and around the world.

BTV/The Life Sciences Report: What is Miraculins Inc.'s focus?

Christopher Moreau: Our business plan is to focus on the in-licensing or acquisition of diagnostic and risk assessment technologies for diseases where there's a significant worldwide need. We have two lead technologies: One is our rapid, needle-free screening device for diabetes called the Scout DS®, and the other is a screening device called PreVu that noninvasively measures cholesterol in the skin as a new biomarker for risk of coronary artery disease. Right now, our primary drive is the establishment of the Scout DS® Diabetes Screen in multiple market channels.

TLSR: How does Miraculins distinguish itself from its competitors?

CM: The most significant differentiator is the technology itself. These are unique, proprietary technologies that have had tens of millions of dollars invested in them, and they fill very important niches in the global healthcare market space. They are the only technologies of their exact kind in the world, and have extensive...

Continue reading this interview with Christopher Moreau and watch the video from BTV: The Diabetes Economy: Miraculins Scouts for Worldwide Markets

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.


Miraculins Inc. paid BTV and The Life Sciences Report to conduct, produce and distribute the interview. Christopher Moreau had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Christopher Moreau and not of BTV, The Life Sciences Report or its officers.

Contact Information

  • Contact Info:
    Brandon Fung
    The Life Sciences Report
    Tel: 707-981-8107